Micromet Q2 revenues up
For the second quarter of 2011, the company has posted net loss of $17.3m, or $0.19 loss per diluted share, compared to $4.06m, or $0.05 loss per diluted
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.